Future research should prioritize the development of personalized treatment algorithms based on individual molecular biomarker profiles, particularly HIF-1α, inflammatory markers, and adipokine patterns, to optimize therapeutic selection for patients with OSA and diabetes. This evidence concerns the gene HIF1A and diabetes mellitus.